J. Moore

3.3k citations

25 papers · 2.4k indexed · 1 hit paper · h-index 14

Oncology top 2%
- Cancer Immunotherapy and Biomarkers 4
- CAR-T cell therapy research 3
- HER2/EGFR in Cancer Research 3
Radiology, Nuclear Medicine and Imaging top 1%
- Monoclonal and Polyclonal Antibodies Research 4
Immunology top 10%
- Immunotherapy and Immune Responses 8
Hematology top 5%
Cancer Research top 10%
Genetics
- Virus-based gene therapy research 3
Surgery
- Esophageal Cancer Research and Treatment 3
Pulmonary and Respiratory Medicine
- Gastric Cancer Management and Outcomes 3

Co-authors: Helen R. Griffiths I. Craig Henderson Debu Tripathy Paul Peter Rosen Nancy T. Sklarin Andrew D. Seidman Sharon A. Baughman José Baselga
Cited by: Oncology Radiology, Nuclear Medicine and Imaging Immunology
Journals: British Journal of Cancer (7 papers)European Journal of Cancer (3 papers)Annals of Oncology (2 papers)
Partner nations: United Kingdom Sweden United States

In The Last Decade

J. Moore

24 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by J. Moore

Since Specialization

Citations

This map shows the geographic impact of J. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Moore more than expected).

Fields of papers citing papers by J. Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Moore. The network helps show where J. Moore may publish in the future.

Co-authorship network

The 25 scholars most cited alongside J. Moore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Moore Line = papers co-authored together J. Moore links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Patient perspectives on key symptoms and preferences for follow-up after upper gastro-intestinal cancer surgery Supportive Care in Cancer ·Philip H. Pucher,Annie E. Coombes,Janet Kusi – Appiah,יעל שגב,J. Moore,Tendai Chari,Jesper Lagergren,Cara Baker,Mark Kelly,James Gossage,Jason Dunn,Sebastian Zeki,Ben Byrne,Jervoise Andreyev,Andrew Davies	2022	1
2	Brain metastasis in advanced colorectal cancer: Results from the South Australian metastatic colorectal cancer (SAmCRC) registry Annals of Oncology ·Timothy Price,Christos S. Karapetis,Tomás Andrade,Gonzalo Tapia Rico,Robert Padbury,Guy J. Maddern,J. Moore,Scott Carruthers,David Roder,Amanda Townsend	2016	3
3	GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): A phase I trial in melanoma Annals of Oncology ·Matthew Vaughan,J. Moore,Шатуева Сара Зинулгабделовна,SR Johnston,Roger A’Hern,Mark Hill,Tim Eisen,Mi-ni Seon,José de Arimatéia Alves Vieira Filho,Martin Gore	2000	13
4	Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy European Journal of Cancer ·R.K. Gregory,Mark Hill,J. Moore,Roger A’Hern,Stephen Johnston,Peter Blake,Zhu Xueping,Desmond P.J. Barton,Martin Gore	2000	17
5	Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study British Journal of Cancer ·Mark Allen,Matthew Vaughan,Andrew Webb,Stephen Johnston,Philip Savage,Tim Eisen,Tania Edwards,J. Moore,Roger A’Hern,Martin Gore	2000	49
6	Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. PubMed ·José Baselga,Debu Tripathy,J. Mendelsohn,Sharon A. Baughman,Christopher C. Benz,Eva-Maria Cattoen,Nancy T. Sklarin,Andrew D. Seidman,C. Hudis,J. Moore,Paul Peter Rosen,Jessica Garfield,I. Craig Henderson,Larry Norton	1999	229
7	Gene Therapy with Autologous, Interleukin 2-Secreting Tumor Cells in Patients with Malignant Melanoma Human Gene Therapy ·Kay Palmer,J. Moore,Batoul Diab,Edward E. Frankel,V P Kolosovskaia,Robert C. Rees,Anna K. Murray,R. Mascari,John M. Kirkwood,Шатуева Сара Зинулгабделовна,XU Hong-ping,J.M. Thomas,Mark Harries,S. Johnston,Mary Collins,Martin Gore	1999	66
8	Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma British Journal of Cancer ·SR Johnston,Lene Dalsten,J. Moore,Corpo di ballo del Teatro Massimo,Roger A’Hern,D. S. MATTESON,A. Karialainen,S.Y. Park	1998	65
9	Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma European Journal of Cancer ·Paul N. Mainwaring,Corpo di ballo del Teatro Massimo,Jenny C. Chang,J. Moore,Barry W. Hancock,P J Guillou,R. Oskam,Martin Gore	1997	2
10	A phase II study of continuous infusional 5-fluorouracil (5-FU) and subcutaneous interleukin-2 (IL-2) in metastatic renal cancer European Journal of Cancer ·Philip Savage,B.H. Fakazi,J. Moore,Martin Gore	1997	10
11	Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.breakdown → Journal of Clinical Oncology ·José Baselga,Debu Tripathy,John Mendelsohn,Sharon A. Baughman,Christopher C. Benz,Eva-Maria Cattoen,Nancy T. Sklarin,Andrew D. Seidman,Clifford A. Hudis,J. Moore,Paul Peter Rosen,Jessica Garfield,I. Craig Henderson,Larry Norton	1996	1088
12	Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer British Journal of Cancer ·Helmout Modjtahedi,Tamas Hickish,Margery Nicolson,J. Moore,Cecilia Valdivia Silva,S. A. Eccles,Phillippi M.A.,Janine Salter,John Sloane,Loreto Spencer,K. Priest,Isabel Smith Zubiaga,Christopher Dean,M. Gore	1996	82
13	A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily British Journal of Cancer ·Philip Savage,Vicki L. Horton,J. Moore,Mary Owens,XU Da-hua,M. Gore	1996	93
14	A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma British Journal of Cancer ·Marwa Mahmoud,Lucas Tadeu Barrak Stangler,Roger A’Hern,A. E. Taylor,Victor P. Letyagin,Corpo di ballo del Teatro Massimo,J. Moore,MC Nicolson,A. Karialainen,M. Gore	1996	7
15	Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2 British Journal of Cancer ·Roger Gooding,Шатуева Сара Зинулгабделовна,D. S. MATTESON,J. Moore,M. Gore	1995	55
16	The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck European Journal of Cancer Part B Oral Oncology ·Mary O’Brien,John B. Schofield,Victor P. Letyagin,J. Moore,Corpo di ballo del Teatro Massimo,J.M. Henk,K.A. MacLennan,Martin Gore	1994	4
17	Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck European Journal of Cancer Part B Oral Oncology ·D. S. MATTESON,Шатуева Сара Зинулгабделовна,D.C. Henderson,K.A. MacLennan,Victor P. Letyagin,J. Moore,J R Hobbs,Martin Gore	1993	13
18	Cisplatin, dacarbazine and tamoxifen for refractory advanced malignant melanoma Melanoma Research ·Mark J. McKeage,Victor P. Letyagin,M. Nicholson,J. Moore,Corpo di ballo del Teatro Massimo,Martin Gore	1993	1
19	Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck British Journal of Cancer ·S.Y. Park,Шатуева Сара Зинулгабделовна,K.A. MacLennan,E O’Brien,J. Moore,D. S. MATTESON,Victor P. Letyagin,R. J. N. Garth,E. Moskovic,Daniel J. Archer,N.M. Breach,Alda Lucia da Costa Camelo,P. Rhys‐Evans,David R. King	1992	9
20	Hyperthermic Oncology 1984 International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine ·Helen R. Griffiths,J. Moore	1985	406

About J. Moore

J. Moore is a scholar working on Oncology, Immunology, Immunology and Allergy, Otorhinolaryngology and Pulmonary and Respiratory Medicine, having authored 25 papers that have together received 2.4k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (8 papers), Cancer Immunotherapy and Biomarkers (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Virus-based gene therapy research (3 papers), CAR-T cell therapy research (3 papers), Esophageal Cancer Research and Treatment (3 papers), HER2/EGFR in Cancer Research (3 papers) and Gastric Cancer Management and Outcomes (3 papers). The work is most often cited by research in Oncology (1.4k citations), Radiology, Nuclear Medicine and Imaging (917 citations), Immunology (383 citations), Hematology (161 citations) and Cancer Research (210 citations). J. Moore has collaborated with scholars based in United Kingdom, Sweden and United States. Frequent co-authors include Helen R. Griffiths, I. Craig Henderson, Debu Tripathy, Paul Peter Rosen, Nancy T. Sklarin, Andrew D. Seidman, Sharon A. Baughman, José Baselga, Larry Norton and Christopher C. Benz. Their work appears in journals such as British Journal of Cancer, European Journal of Cancer, Annals of Oncology, British journal of surgery and Human Gene Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact